Vasopressin is typically added to norepinephrine when the norepinephrine dose reaches 0.25 to 0.5 mcg/kg/min and the patient’s mean arterial pressure (MAP) still hasn’t reached the target of at least 65 mm Hg. This threshold, endorsed by the Surviving Sepsis Campaign, translates to roughly 17.5 to 35 mcg/min in an average 70 kg patient. The goal is to bring in a second vasopressor that works through a completely different mechanism before norepinephrine doses climb into ranges where side effects become more dangerous.
The Recommended Threshold
The Surviving Sepsis Campaign guidelines suggest adding vasopressin as an adjunct when norepinephrine alone cannot maintain a MAP of 65 mm Hg, or when you want to reduce the total norepinephrine burden. The specific trigger point is a norepinephrine infusion rate of 0.25 to 0.5 mcg/kg/min. That range is deliberately broad because the decision also depends on the clinical trajectory: a patient whose pressure is deteriorating rapidly may warrant earlier addition than one who is slowly drifting.
A recent retrospective study specifically examined whether initiating vasopressin at different points within that dose window affected outcomes in patients with high organ dysfunction scores. The takeaway reinforces that waiting too long, past the upper end of that range, may reduce the benefit of adding vasopressin. In practice, many ICU protocols trigger vasopressin initiation closer to the 0.25 mcg/kg/min mark rather than waiting until 0.5.
Why Vasopressin Works Differently
Norepinephrine is a catecholamine. It raises blood pressure by stimulating receptors on blood vessels and the heart, but at high doses it increases heart rate, oxygen demand, and the risk of dangerous heart rhythms. Vasopressin sidesteps all of that. It acts on a completely separate set of receptors (V1 receptors) on blood vessel walls to cause constriction, and it does so without revving up the heart. In fact, vasopressin can slightly lower heart rate through a reflex response, which improves the heart’s filling time between beats.
There’s also a physiological rationale specific to septic shock. Early in sepsis, the body releases its own vasopressin stores as a natural defense. But after prolonged shock, those stores become depleted, and blood levels of vasopressin drop paradoxically low. Adding exogenous vasopressin essentially replaces a hormone the body has run out of, which helps restore the blood vessels’ ability to constrict. This is why it’s sometimes called “replacement dose” vasopressin rather than a traditional escalation of vasopressor therapy.
The practical result is a norepinephrine-sparing effect: once vasopressin is on board, clinicians can often reduce the norepinephrine dose while maintaining the same blood pressure target. Lower catecholamine exposure means less strain on the heart and a lower risk of arrhythmias.
Standard Dosing and How It’s Given
Unlike norepinephrine, vasopressin is usually started at a fixed dose rather than titrated up and down in real time. A common starting rate is 0.03 units/min (1.8 units/hr). If the MAP goal isn’t reached within about four hours, some protocols allow an increase to a maximum of 0.04 units/min (2.4 units/hr). Meanwhile, norepinephrine continues to be titrated as needed alongside it.
This fixed-dose approach reflects how vasopressin is used in the major clinical trials. It’s not meant to replace norepinephrine but to work alongside it, allowing the norepinephrine dose to come down while the two agents together maintain adequate perfusion pressure.
What the Major Trials Found
The two landmark trials, VASST and VANISH, tested whether adding vasopressin improves survival compared to using norepinephrine alone.
The VASST trial, published in the New England Journal of Medicine, enrolled patients already on catecholamine vasopressors and randomized them to receive either low-dose vasopressin or additional norepinephrine. Overall 28-day mortality was 35.4% in the vasopressin group versus 39.3% in the norepinephrine group, a difference that did not reach statistical significance. However, a pre-planned subgroup analysis told a more nuanced story: among patients with less severe septic shock (those on lower doses of norepinephrine at enrollment), vasopressin reduced 28-day mortality to 26.5% compared with 35.7% for norepinephrine alone. Patients already in more severe shock saw no mortality difference. This finding supports the idea that adding vasopressin earlier, before shock becomes refractory, may be where the real benefit lies.
The VANISH trial, published in JAMA, tested vasopressin as a first-line agent versus norepinephrine. It found no significant difference in kidney failure-free days between the two groups. But one notable finding stood out: patients who received vasopressin were less likely to need dialysis (25.4% versus 35.3%). The overall rate of kidney failure was similar between groups, so vasopressin didn’t prevent kidney injury, but it appeared to reduce the severity enough that fewer patients required renal replacement therapy.
Risks to Watch For
A meta-analysis pooling data from multiple trials found that overall adverse events were not significantly different between patients who received vasopressin and those who did not. The one clear exception was digital ischemia, which refers to reduced blood flow to the fingers and toes. Patients receiving vasopressin had nearly five times the risk of developing digital ischemia compared to controls. This happens because vasopressin constricts small peripheral blood vessels, and in patients who are already in shock with compromised circulation, the fingers and toes are vulnerable.
Other complications that clinicians monitor for, including mesenteric ischemia (reduced blood flow to the gut), cardiac events, arrhythmias, and low sodium levels, did not occur at significantly higher rates with vasopressin in pooled trial data. That said, higher vasopressin doses have been associated with ischemia affecting the gut, heart, and extremities in individual reports, which is one reason the dose is kept in the low, fixed range described above.
When Vasopressin May Not Be Appropriate
Vasopressin raises blood pressure purely through vasoconstriction. It has no ability to make the heart pump harder. This means it increases the workload the heart has to pump against (afterload) without providing any compensatory boost to cardiac output. In patients whose shock is driven primarily by a failing heart rather than by vasodilation, adding vasopressin can make things worse. Patients with significant left ventricular dysfunction need careful evaluation, often with echocardiography, before vasopressin is started.
Pulmonary hypertension is another scenario requiring caution. Because vasopressin constricts the pulmonary vasculature, it can worsen right heart strain in patients who already have elevated pressures in the lungs. In these situations, the decision to add vasopressin depends heavily on real-time assessment of heart function and hemodynamic monitoring.
Putting the Timing Together
The convergence of guideline recommendations and trial evidence points toward a clear pattern. The trigger for adding vasopressin is a norepinephrine dose in the range of 0.25 to 0.5 mcg/kg/min with an MAP still below 65 mm Hg. Starting it earlier within that window, rather than later, aligns with the VASST subgroup data showing benefit in less severe shock. The vasopressin itself is given at a low, relatively fixed dose (0.03 to 0.04 units/min), and the primary goal is to achieve MAP targets while reducing the total catecholamine load. The tradeoff is a meaningful increase in the risk of digital ischemia, which requires close monitoring of extremities throughout the infusion.